Patiromer With or Without Food for the Treatment of Hyperkalemia

PHASE4CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions
Hyperkalemia
Interventions
DRUG

patiromer

8.4 g/day starting dose, administered orally

Trial Locations (29)

11355

Investigator Site 37, Flushing

32132

Investigator Site 30, Edgewater

33012

Investigator Site 10, Hialeah

33015

Investigator Site 15, Miami

33021

Investigator Site 13, Hollywood

33028

Investigator Site 18, Pembroke Pines

33147

Investigator Site 43, Miami

33319

Investigator Site 16, Lauderdale Lakes

33614

Investigator Site 27, Tampa

38305

Investigator Site 40, Jackson

48504

Investigator Site 23, Flint

60504

Investigator Site 39, Aurora

64111

Investigator Site 34, Kansas City

73069

Investigator Site 36, Norman

75231

Investigator Site 33, Dallas

78202

Investigator Site 26, San Antonio

78207

Investigator Site 29, San Antonio

78215

Investigator Site 28, San Antonio

78229

Investigator Site 25, San Antonio

80230

Investigator Site 24, Denver

83642

Investigator Site 44, Meridian

84124

Investigator Site 22, Salt Lake City

89106

Investigator Site 41, Las Vegas

91773

Investigator Site 21, San Dimas

92262

Investigator Site 38, Palm Springs

92505

Investigator Site 20, Riverside

92648

Investigator Site 11, Huntington Beach

92708

Investigator Site 12, Fountain Valley

33313-1638

Investigator Site 17, Lauderdale Lakes

All Listed Sponsors
lead

Relypsa, Inc.

INDUSTRY

NCT02694744 - Patiromer With or Without Food for the Treatment of Hyperkalemia | Biotech Hunter | Biotech Hunter